Navigation Links
Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
Date:3/3/2008

have also made good progress in the major collaborative agreement signed in March 2006, which granted Pfizer exclusive rights to apply NicOx' nitric oxide-donating technology across the entire field of ophthalmology. This collaboration involves several separate projects focused on major ocular diseases and encouraging results have been observed in the most advanced program. During 2007, NicOx received euro 3.0 million from Pfizer in research funding for the second year of this collaboration and Pfizer has subsequently signed a one-year extension of the research phase of this agreement, which will result in NicOx receiving a further euro 3 million in research funding in March 2008.

Clinical program initiated for new nitric oxide-donating anti-hypertensive agents

In July 2007, the program to develop new nitric oxide-donating antihypertensive agents entered clinical development, with the initiation of the first in a series of planned studies for the first selected drug candidate. These clinical studies are covered by a major agreement between NicOx and Merck & Co., Inc., which covers nitric oxide-donating derivatives of several major classes of antihypertensive agents. Merck and NicOx selected the first candidate in January 2007 and IND-enabling toxicology studies were subsequently initiated and an IND was filed in May. The achievement of these milestones resulted in NicOx receiving euro 10.0 million in payments from Merck during 2007.

TPI 1020 advanced into a phase 2 proof-of-concept study by Topigen

In November 2007, TOPIGEN Pharmaceuticals Inc. dosed the first patients in a phase 2 proof-of-concept study for TPI 1020 (formerly NCX 1020) in Chronic Obstructive Pulmonary Disease (COPD). This study is expected to provide the first assessment of TPI 1020's potential activity in COPD. TPI 1020 is a novel respiratory anti-inflammatory, which was licensed by Topigen from NicOx.

In September 2007, TPI 1020 delivered promising top-line res
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
3. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
4. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
5. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
6. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
7. Biopure Announces 2007 Third Quarter Financial Results
8. Xytis Names Gordon H. Busenbark as Chief Financial Officer
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Pharmacopeia Announces Third Quarter 2007 Financial Results
11. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Tasly Pharmaceuticals, Inc., the world,s leader in ... the launch of Deepure. Deepure is ... and women concerned with supporting their overall health ... while helping keep their health care cost down.  ... formulas, namely, ProHeart PLUS, ImmunoPower PLUS, and Pro-Memory ...
(Date:9/30/2014)... 2014 Aileron Therapeutics, Inc. - Product ... Markets Direct,s, ,Aileron Therapeutics, Inc. - Product Pipeline ... Aileron Therapeutics, Inc.,s pharmaceutical research and development focus. ... current therapeutic developmental pipeline of Aileron Therapeutics, Inc.,s, ... assessment by drug target, mechanism of action (MoA), ...
(Date:9/30/2014)... , September 30, 2014 ... research report the "Glycobiology/Glycomics Market by Product [Enzymes ... MALDI-TOF), Kits, and Reagents], Application (Immunology, Oncology) ... to 2019", published by MarketsandMarkets, provides a ... challenges, opportunities, current market trends, and strategies ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... Orally Dissolving Film StripBioAlliance to Resubmit Loramyc(R) NDA WOODCLIFF ... products division of a wholly owned subsidiary of Par ... provides an update on two of its pipeline products. ... 7, 2009, Strativa submitted a New Drug Application (NDA) ...
... April 8 Phase III data, published online this ... Metabolism , showed that arzoxifene, an investigational selective estrogen ... Company (NYSE: LLY ), significantly increased lumbar ... postmenopausal women with normal or low bone mass, versus ...
Cached Medicine Technology:Strativa Pharmaceuticals Provides Product Pipeline Update 2Strativa Pharmaceuticals Provides Product Pipeline Update 3Strativa Pharmaceuticals Provides Product Pipeline Update 4Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 2Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 3Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 4
(Date:9/30/2014)... in 2003 to slow the spiraling costs of drugs ... patients has had no meaningful impact on cancer chemotherapy ... Journal of Clinical Oncology published online today. ... treat colorectal and lung cancers, and did not find ... following the implementation of the recent Medicare law in ...
(Date:9/30/2014)... York, NY (PRWEB) September 30, 2014 ... falling demand have hampered growth in the Bread ... diets have caused consumers to moderate their consumption ... consumer preferences for premium varieties shrunk the market ... products. Successful operators proactively responded by introducing more ...
(Date:9/30/2014)... Federally Qualified Health Centers (FQHCs) granted new patient ... higher rates than other primary care practices (non-FQHCs), ... to results of a new 10-state University of ... Care . , Using data from a previous ... the investigators found that FQHCs community health ...
(Date:9/30/2014)... of allergy-related sudden deaths in the U.S., according to ... conducted by researchers at Montefiore Medical Center ... Yeshiva University . The study, published online today in ... also found that the risk of fatal drug-induced allergic ... and that such deaths increased significantly in the U.S. ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 ... Blue Star Nutraceuticals designed to help maximize lean, strong ... optimizes the body’s absorption of glucose has caught the ... , “The main purpose behind Glycodrive is to help ... lean muscle,” reports Michaels. “Carbs are essential in the ...
Breaking Medicine News(10 mins):Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2
... BFRM ) today announced its financial results for the ... of fiscal,year 2008. Net sales were $18.6 million for the ... the quarter ended December 31, 2006,an increase of $6.8 million ... ended December 31, 2007 as compared to $2.7 million for ...
... Mass., Jan. 31 Millennium,Pharmaceuticals, Inc. (Nasdaq: ... presentation,at the 2008 Merrill Lynch Global Pharmaceutical, ... live and may be accessed by visiting ... http://www.millennium.com ., (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ...
... Jan. 31 In hopes of gaining a better,grasp ... focusing more on sales training tools and techniques to,provide ... reps,the first year of training and preparation is critical ... rep of approximately $10,500 in,the first year of employment, ...
... January 31, 2008 All candidates running for office in ... care system for the United States that is second to ... its annual report on The State of the Nations Health ... designed to gain candidate commitments to support a series of ...
... KENILWORTH, N.J., Jan. 31 Schering-Plough,Corporation (NYSE: ... antifungal agent NOXAFIL(R),(posaconazole) Oral Suspension received an ... invasive Aspergillus infections in certain,high- risk patients ... Guidelines of the Infectious Diseases Society of ...
... ovarian failure, researchers report , , THURSDAY, Jan. 31 (HealthDay ... that prompts early menopause and might account for some ... that,s known for suppressing tumor growth -- apparently also ... quickly. When researchers deleted the PTEN gene in mice, ...
Cached Medicine News:Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 2Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 3Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 4Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 5Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 6Health News:BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008 7Health News:2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation 2Health News:Vital Training Tools Elevate New Pharmaceutical Sales Reps into Top Performers During Critical First Year 2Health News:Achieving a US health care system 'second to none' 2Health News:Achieving a US health care system 'second to none' 3Health News:Achieving a US health care system 'second to none' 4Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 2Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 3Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 4Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 5Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 6Health News:Study Spots Gene That Plays Role in Infertility 2
... to optimize the accuracy and precision of ... is widely recognized by customers throughout the ... over the years and now covers a ... including filter tips, certified pure tips, stepper ...
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
... racks of 96 tips, Sterilized Diamond- Tips ... Sterilized Diamond Tips are irradiated by gamma-rays ... with a certificate of sterilization, specifying the ... certified free of detectable Rnase, Dnase, DNA, ...
... of 96 tips, Sterilized Diamond- Tips are ... Diamond Tips are irradiated by gamma-rays for ... a certificate of sterilization, specifying the date ... free of detectable Rnase, Dnase, DNA, RNA, ...
Medicine Products: